Nikhil Ghatnekar, DO
Interventional Cardiology · Riverside, CANPI 1194170290
Payments from drug & device makers
Across 264 payments — averaging $102.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Medtronic$6K
- Abbott$5K
- Boston Scientific$4K
- Abiomed$3K
- Shockwave Medical, Inc$977
- plus $3K from 23 others
Across 1 payment — averaging $56.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$56
What the payments were for
- Consulting fees$1,5906%
- Grants$1,2305%
- Travel & lodging$11,06141%
- Food & beverage$12,69247%
- Education$5422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 34 | $5,760 |
| Medtronic(2 entities) | 69 | $5,541 |
| Abbott | 41 | $5,355 |
| Boston Scientific | 14 | $3,915 |
| Abiomed | 37 | $2,502 |
| Shockwave Medical, Inc | 9 | $977 |
| Philips North America LLC | 8 | $634 |
| Cardiovascular Systems Inc. | 3 | $393 |
| Johnson & Johnson | 4 | $230 |
| Stryker | 10 | $216 |
| Chiesi USA, Inc. | 3 | $200 |
| Asahi Intecc USA, Inc. | 1 | $180 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $163 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $159 |
| Terumo Medical Corporation | 2 | $127 |
| Novartis | 5 | $106 |
| Penumbra, Inc. | 1 | $103 |
| Inari Medical, Inc. | 1 | $81 |
| Cumberland Pharmaceuticals, Inc. | 1 | $80 |
| Atricure, Inc. | 1 | $72 |
| Viiv Healthcare Company | 4 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Cook Medical LLC | 1 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| W. L. Gore & Associates, Inc. | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Cvrx, Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,212
- XIENCE SKYPOINT$1,686
- Impella$1,559
- HeartMate Touch$1,320
- GENERAL ATHERECTOMY$1,230
- GENERAL VASCULAR ACCESS$1,215
- SAPIEN 3 Ultra RESILIA$1,196
- COREVALVE EVOLUT R$1,141
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$907
- TurboHawk$678
- OPTIS$570
- Diamondback Coronary$420
- ENSITE$326
- SYMPLICITY G3$309
- Micra$264
- AngioJet Ultra 5000A$195
- ASAHI PTCA Guide Wire$180
- ENSITE PRECISION$166
- Diamondback Peripheral$162
- RhythmVIEW Work Stations$145
How this compares
$27,114 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $435,875 |
| EntrestoSacubitril/Valsartan | 80 | $114,771 |
| FarxigaDapagliflozin Propanediol | 76 | $96,335 |
| XareltoRivaroxaban | 71 | $91,187 |
| MultaqDronedarone Hcl | 28 | $42,016 |
| JardianceEmpagliflozin | 20 | $28,595 |
| BrilintaTicagrelor | 18 | $18,420 |
| DapagliflozinDapagliflozin Propanediol | 20 | $17,010 |
| Repatha SureclickEvolocumab | 16 | $12,438 |
| InpefaSotagliflozin | 11 | $7,532 |
| Amiodarone Hcl | 59 | $7,242 |
| Metoprolol Succinate | 435 | $6,956 |
| Atorvastatin Calcium | 363 | $5,268 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 89 | $2,851 |
| Spironolactone | 278 | $2,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $106 | $114,77180 claims |
| Johnson & JohnsonXarelto | $230 | $91,18771 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $48 | $7,53211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Riverside
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.